News

Neurotech Pharmaceuticals, a biotechnology company, has announced that the company’s lead product candidate, NT-501, substantially slowed the loss of vision in a Phase II clinical trial in subjects

Agfa HealthCare said that the new cardiology system will include solutions for adult and pediatric echocardiography, cardiac catheterization, and vascular ultrasound. IMPAX Cardiovascular provides diagnosticians with a single

Western Maryland Regional Medical Center (WMHS) will rely on Agfa HealthCare’s IMPAX Cardiovascular (IMPAX CV) for all cardiology studies, including cardiac catheterization imaging and echocardiography imaging and reporting.

At December 31, 2008, the company had liquid funds available for operating activities, comprised of cash and cash equivalents together with current investments, of $3.7 million, compared to

Endocyte, a biotechnology company, has announced positive interim results from an ongoing Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer. The single

Trubion Pharmaceuticals, a biopharmaceutical company, has announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth, has initiated a Phase I clinical trial of SBI-087, Trubion’s next

GPC Biotech, a biopharmaceutical company, has reported a net loss of E9.04m, or E0.25 per share, for the fourth quarter of 2008, compared to a net loss of

Poniard Pharmaceuticals, a biopharmaceutical company, has reached its enrollment target of 400 patients in the Spear trial. This global, pivotal Phase III trial is evaluating the efficacy and

Foley will continue as an employee through December 31, 2009 and will serve as a special advisor to the company during this time and in support of Quidel’s